Product logins

Find logins to all Clarivate products below.


Alzheimer’s Disease | Access and Reimbursement | EU5 | 2017

Alzheimer’s disease (AD) is a chronic neurodegenerative condition widely recognized as a global health crisis; as the general population ages and AD prevalence grows, the need for drugs to treat, delay, or stop the disease is paramount. While current therapies used to treat AD are generically available in Europe, the next five years look set to bring several premium-priced new brands addressing the cognitive as well as the behavioral symptoms of AD. This research examines the current impact of payer policy on prescribing and probes how neurologists and cost-conscious European payers will react to novel agents that, while innovative, will drive up healthcare costs considerably.

Related Market Assessment Reports

Report
Alzheimer’s Disease – Access & Reimbursement – Access & Reimbursement – Alzheimer’s Disease (US)
Eisai / Biogen’s Leqembi (lecanemab) and Eli Lilly’s Kisunla (donanemab) are vying to capitalize on the potential for a disease-modifying therapy (DMT) in Alzheimer’s disease (AD), and…
Report
Alzheimer’s Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Alzheimer’s Disease (US)
Until recently, approved treatments for Alzheimer’s disease (AD) primarily consisted of approved procognitive symptomatic drugs (e.g., donepezil, memantine), as well as off-label antidepressants…
Report
Alzheimer’s Disease – Landscape & Forecast – Disease Landscape & Forecast (G7)
Eisai / Biogen’s Leqembi (lecanemab) has launched for the treatment of early AD in the United States and Japan. Although EMA’s CHMP has approved the drug EC’s approval is still pending. Eli…
Report
Alzheimer’s Disease – Unmet Need – Unmet Need – Agitation in Alzheimer’s Disease (US/EU)
Agitation affects most Alzheimer’s disease (AD) patients and comprises a constellation of disruptive symptoms for patients and their families, which may contribute to nursing home placement…
Report
Alzheimer’s Disease – Unmet Need – Unmet Need – Early Alzheimer’s Disease (US/EU)
Eisai / Biogen’s lecanemab (Leqembi) and Eli Lilly’s donanemab (Kisunla) are modestly effective in reducing cognitive and functional decline, require frequent IV infusions, and carry ARIA-…